Stocks● Neutral
Bombay High Court Blocks 'Esiraft' to Protect Sun Pharma Brand
The court ruled the mark too similar to Sun Pharma’s 'Raciraft,' halting Meghmani Lifesciences. This win secures brand equity and long-term revenue stability.
Continue with
Pharmaceutical Intellectual Property Rights Score a Win for Sun Pharma
In a decisive ruling for intellectual property protection within the domestic pharmaceutical sector, the Bombay High Court has granted interim relief to Sun Pharmaceutical Industries (SUNPHARMA.NS). The court has issued an injunction barring Meghmani Lifesciences from utilizing the product mark 'Esiraft,' citing significant similarities to Sun Pharma’s established brand, 'Raciraft.'
For investors and market analysts, this development underscores the aggressive stance major pharmaceutical players are taking to defend their brand equity and market share. The litigation, which centered on allegations of trademark infringement and passing off, highlights the critical importance of brand differentiation in a crowded market where phonetic and visual similarity can lead to consumer confusion—a risk that carries both legal and safety implications.
The Court’s Rationale: Phonetic and Visual Overlap
In the proceedings, Sun Pharma argued that the mark 'Esiraft,' used by Meghmani Lifesciences, was deceptively similar to its own registered trademark, 'Raciraft.' The Bombay High Court, after evaluating the evidence, concurred with Sun Pharma’s assertions.
The court determined that the marks were both visually and phonetically indistinguishable enough to create a high probability of confusion among consumers and healthcare professionals. In the pharmaceutical industry, where brand recognition is closely tied to therapeutic application and patient safety, such confusion is viewed as a material threat to the original developer’s market position.